Human monoclonal antibodies against orexin receptor type 1

US10758615B2 · kind B2 · utility

Assignees

• INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
• UNIVERSITÉ PARIS DIDEROT—PARIS 7 · FR
• INSTITUT REGIONAL DU CANCER DE MONTPELLIER (ICM) · FR
• Universite De Montpellier · FR

Inventors

• Alain COUVINEAU · Paris, FR
• Thierry VOISIN · Paris, FR
• Pascal NICOLE · Paris, FR
• Bruno Robert · Montpellier, FR
• Pierre MARTINEAU · Montpellier, FR
• Myriam CHENTOUF · Montpellier, FR

Key dates

• Filing date: Jan 14, 2016
• Grant date: Sep 1, 2020
• Expiry date: Aug 25, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/73
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates to human monoclonal antibodies against orexin receptor type 1 (OX1R, hyprocretin 1) and uses thereof for the treatment of cancer. The antibodies are characterized by their CDRs: NYYMN, YISGSSRNIYYADFVKG, SNYDGMDV (Heavy chain) and AGTSSDVGGSNYVS, PGKAP, SSYTYYSTRV (Light Chain)) or the CDRS having at least 50% or 70% identity with the above listed sequences.